Skip to navigation | Skip to main content | Skip to footer
Menu
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Professor Andrew Hughes (MA PhD MRCP FFPM PGCert) - personal details

Contact details

Professor Andrew Hughes

Role: Professor of Experimental Cancer Medicine

Tel: +44 7900 184992

Location:

The Christie NHS Foundation Trust

Wilmslow Road

Manchester

M20 4BX

Telephone: +44 16 1918 7896

Websites

 

Biography

Professor Andrew Hughes leads the experimental cancer medicine team at The Christie. This role involves overseeing the clinical contribution to Phase 1 cancer clinical trials and a strategic growth of the research by up to 10 fold over the next 5 years. Previous to that Andrew was Global VP of early clinical development at AstraZeneca Pharmaceuticals leading over 50 research and early clinical development programmes of novel candidate drugs. He graduated with double first in medical sciences at Cambridge, spending 3 years as a Tutor in Physiology and Bye-fellow of Downing College, Cambridge, whilst completing a PhD in behavioural neuroendocrinology in the Department of Anatomy. He subsequently practised general clinical medicine in Manchester’s teaching hospitals in the UK, joining Zeneca in 1994 from being a registrar in Cardiology, and until recently continued with clinical work. Within the industry, he has had responsibilities on the corporate pain control drug development board and in setting the limits of human exposure based on existing pre-clinical and clinical data for all development products. Since 2001 he has been accountable for the early phase clinical development of AstraZeneca’s oncology compounds in volunteers and patients, and has been clinical investigator on over 200 clinical trials. He is approved by the Resuscitation Council (UK) as a director in Advanced Cardiac Life Support, and regularly teaches health professionals in ACLS. During 2002-3 he served on the board of the Faculty of Pharmaceutical Medicine, UK; and has the responsibility for the clinical pharmacology revision module for those physicians sitting the Diploma of Pharmaceutical Medicine. He is a former member of the board of NCRI, on the editorial committee for Annals of Oncology and on the Steering Committee for the FDA Biomarkers Consortium. In November 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He serves on CRUK’s Biomarkers evaluation research panel and MRC’s translational medicine grant awarding bodies.

Memberships of Committees and Professional Bodies

  • American Society of Clinical Oncology
  • Fellow Faculty Pharmaceutical Physicians
  • American Association of Cancer Research
  • British Pharmacological Society
  • CRUK BIDD committee member 
  • Board Member, ABPI Cancer group
  • MRC DPFS committee member

Qualifications

  • MA Anatomy, Cambridge
  • PhD Neurosciences, Cambridge
  • MB ChB (Hons), Manchester
  • MRCP, Royal College Physicians, London
  • FFPM, Royal College Physicians, London
  • PGDip Clinical Pharmacology, Guildford

Role

Strategic Lead, Experimental Cancer Medicine Team, The Chrsitie

Co-lead on Experimental Therapeutics in support of BRC

MCRC Steering Group member; architect in Human Tissue Bank and Pre-operative Trials. Co-supervisor of CRUK and Wellcome Clinical fellowship schemes; and Director of MRes in Experimental Cancer Medicine. Member of CRUK BMERP funding committee and MRC reviewer

 

Teaching

  • MRes Experimental Cancer Medicine
  • PhD clinical fellowships with CRUK and Wellcome